Abivax Stock: Surge of Over 5% Driven by Exceptional Annual Momentum
Abivax stock has made significant gains this Thursday morning, rising 5.3% to reach 103.40 euros at the opening of the Paris session. The French biotech company has shown an impressive trajectory over the past year, soaring more than 1,500%. This rebound follows several consecutive sessions of gains, with the stock having risen nearly 9% over the past seven days.
Current Technical Levels
Abivax stock is currently priced at 103.40 euros, almost touching its 50-day moving average at 103.76 euros. This technical level is a key benchmark: a sustained crossing above this threshold could signal a resumption of the medium-term upward trend, while a rejection would confirm the consolidation phase observed in recent weeks. However, the stock remains significantly above its 200-day moving average, set at 62.52 euros, reflecting the strength of the upward movement initiated over the past year. The RSI, an indicator measuring the speed of price changes, is at 43, a neutral level that signals neither overbuying nor overselling. This moderate reading leaves room for potential progress before reaching technically overheated zones. The most relevant support is at 93.70 euros, a floor that has supported recent pullbacks.
Performance Over the Last Twelve Months
Over the past twelve months, Abivax's performance stands out with a gain of 1,521%, placing the stock among the highest variations on the Paris stock market. In the shorter term, the stock has gained nearly 15% over three months, confirming the persistence of the buying momentum despite regular consolidation phases. The monthly volatility stands at 11.69, a level that reflects significant variation amplitudes, characteristic of biopharmaceutical companies whose valuation closely depends on the progress of their clinical programs. Moreover, a negative beta of -0.25 indicates that the stock moves largely uncorrelated with the market as a whole. This specificity reflects the unique risk profile of biotechs, whose price catalysts are primarily linked to therapeutic trial results and regulatory decisions rather than macroeconomic cycles.
